A Double Blind, Placebo-Controlled, Randomized Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Subjects
Latest Information Update: 03 Feb 2015
At a glance
- Drugs JNJ 49122944 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Jan 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Nov 2014 New trial record